ReWalk Robotics (LFWD) & Its Peers Critical Contrast

ReWalk Robotics (NASDAQ:LFWD) is one of 44 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it contrast to its competitors? We will compare ReWalk Robotics to related businesses based on the strength of its valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and earnings.

Earnings and Valuation

This table compares ReWalk Robotics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ReWalk Robotics	$13.85 million	-$22.13 million	-1.82
ReWalk Robotics Competitors	$1.58 billion	$173.59 million	32.38

ReWalk Robotics’ competitors have higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings for ReWalk Robotics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReWalk Robotics	0	0	1	0	3.00
ReWalk Robotics Competitors	340	1169	2240	98	2.54

ReWalk Robotics currently has a consensus target price of $21.00, indicating a potential upside of 301.53%. As a group, “Surgical appliances & supplies” companies have a potential upside of 2.43%. Given ReWalk Robotics’ stronger consensus rating and higher possible upside, equities analysts plainly believe ReWalk Robotics is more favorable than its competitors.

Risk & Volatility

ReWalk Robotics has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, ReWalk Robotics’ competitors have a beta of 0.86, suggesting that their average share price is 14% less volatile than the S&P 500.

Institutional & Insider Ownership

26.8% of ReWalk Robotics shares are held by institutional investors. Comparatively, 47.7% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 2.1% of ReWalk Robotics shares are held by insiders. Comparatively, 8.7% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ReWalk Robotics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReWalk Robotics	-159.76%	-28.19%	-23.29%
ReWalk Robotics Competitors	-65.16%	-71.96%	-13.50%

Summary

ReWalk Robotics competitors beat ReWalk Robotics on 8 of the 13 factors compared.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.